Atellica® IM Anti-HBe2 Assay

FDA Premarket Approval P200017 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

DeviceAtellica® IM Anti-HBe2 Assay
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSiemens Healthcare Diagnostics, Inc.511 Benedict Avenuetarrytown, NY 10591-5097 PMA NumberP200017 Supplement NumberS002 Date Received03/22/2022 Decision Date03/29/2022 Product Code LOM  Advisory Committee Microbiology Supplement Type30-day Notice Supplement Reason Process Change - Manufacturer/sterilizer/packager/supplier Expedited Review Granted? No
Date Received2022-03-22
Decision Date2022-03-29
PMAP200017
SupplementS002
Product CodeLOM 
Advisory CommitteeMicrobiology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination ProductNo
Applicant AddressSiemens Healthcare Diagnostics, Inc.
511 Benedict Avenue
tarrytown, NY 10591-5097 PMA NumberP200017 Supplement NumberS002 Date Received03/22/2022 Decision Date03/29/2022 Product Code LOM  Advisory Committee Microbiology Supplement Type30-day Notice Supplement Reason Process Change - Manufacturer/sterilizer/packager/supplier Expedited Review Granted? No Combination ProductNo Approval Order Statement  
to Manufacture An Instrument Component At Another Location

Supplemental Filings

Supplement NumberDateSupplement Type
P200017Original Filing
S002 2022-03-22 30-day Notice
S001 2021-08-10 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
00842768022678 P200017 001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.